Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
The effect of botulinum toxin A in the subscapular muscle in stroke patients with shoulder complaints: a randomised controlled trial
ISRCTN ISRCTN28311224
ClinicalTrials.gov identifier
Public title The effect of botulinum toxin A in the subscapular muscle in stroke patients with shoulder complaints: a randomised controlled trial
Scientific title
Acronym N/A
Serial number at source p02.133
Study hypothesis We assume that relaxation of the subscapular muscle will lead to pain reduction and improvement of mobility in stroke patients with shoulder- or arm-pain and limited range of motion of the shoulder.
Lay summary
Ethics approval Ethics approval received from the local medical ethics committee
Study design Randomised, placebo controlled, parallel group, triple blinded, multicentre trial
Countries of recruitment Netherlands
Disease/condition/study domain Complaints of arm, complaints of shoulder
Participants - inclusion criteria 1. Stroke shoulder- or arm pain longer than one week
2. Visual Analogue Scale (VAS) pain four or higher
3. Glenohumeral exorotation on the affected side is limited to 50% compared to the uninvolved side
4. 18 years or older
Participants - exclusion criteria 1. Patients that cannot answer the pain questions
2. Patients that cannot sit
Anticipated start date 01/11/2002
Anticipated end date 01/11/2006
Status of trial Completed
Patient information material
Target number of participants 50
Interventions Injection of 100 units of BOTOX (R) or 0.9% saline in subscapular muscle.
Primary outcome measure(s) 1. Pain score (VAS)
2. Range of motion of glenohumeral joint
Secondary outcome measure(s) No secondary outcome measures
Sources of funding Allergan (The Netherlands)
Trial website
Publications
Contact name Dr  H J  Arwert
  Address Medical Centre Haaglanden
P.O. Box 432
  City/town Den Haag
  Zip/Postcode 2501 CK
  Country Netherlands
  Tel +31 (0)70 330 2000
  Email h.arwert@mchaaglanden.nl
Sponsor Medical Centre Haaglanden (The Netherlands)
  Address Department of Rehabilitation
P.O. Box 432
  City/town Den Haag
  Zip/Postcode 2501 CK
  Country Netherlands
  Email info@mchaaglanden.nl
  Sponsor website: http://www.mchaaglanden.nl/
Date applied 20/12/2005
Last edited 29/03/2007
Date ISRCTN assigned 20/12/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central